(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
1 November 2012 (01.11.2012)

WIPO | PCT

(10) International Publication Number
WO 2012/148952 A1

(51) **International Patent Classification**:
C12N 15/113 (2010.01) *A61P 35/00* (2006.01)

(21) **International Application Number**:
PCT/US2012/034880

(22) **International Filing Date**:
25 April 2012 (25.04.2012)

(25) **Filing Language**: English

(26) **Publication Language**: English

(30) **Priority Data**:
61/478,767 25 April 2011 (25.04.2011) US
61/565,779 1 December 2011 (01.12.2011) US

(71) **Applicant** *(for all designated States except US)*: **REGULUS THERAPEUTICS INC** [US/US]; 3545 Johns Hopkins Court, San Diego, California 92121 (US).

(72) **Inventor; and**
(75) **Inventor/Applicant** *(for US only)*: **BHAT, Balkrishen** [IN/US]; 3545 Johns Hopkins Court, San Diego, California 92121 (US).

(74) **Agent**: **SCARR, Rebecca B.**; 2275 Deming Way, Ste 310, Middleton, Wisconsin 53562 (US).

(81) **Designated States** *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) **Designated States** *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*

— *with sequence listing part of description (Rule 5.2(a))*

WO 2012/148952 A1

(54) **Title**: MICRORNA COMPOUNDS AND METHODS FOR MODULATING MIR-21 ACTIVITY

(57) **Abstract**: Described herein are compositions and methods for the inhibition of miR-21 activity. The compositions have certain nucleoside modification patterns that yield potent inhibitors of miR-21 activity. The compositions may be used to inhibit miR-21, and also to treat diseases associated with abnormal expression of miR-21, such as fibrosis and cancer.